Novartis Taps Antares in a $1.9B Hunt for Untreatable Cancer Therapies

BOSTON, MA – June 24, 2026 – In a move that sends a clear signal about the future of oncology, pharmaceutical giant Novartis has entered a strategic collaboration with Antares Therapeutics, a young and promising biotechnology firm. The deal, potentially worth up to $1.9 billion, aims to conquer one of modern medicine’s most formidable challenges: designing drugs for cancer targets long considered “undruggable.”

Announced today, the partnership grants Novartis access to Antares' proprietary drug discovery engine. In return, Antares receives a substantial $105 million upfront payment, with the potential for an additional $1.8 billion in milestone payments and royalties. This alliance goes beyond a simple financial transaction; it represents a convergence of big pharma’s scale and a nimble biotech’s specialized innovation, a partnership that could ultimately unlock entirely new ways to treat cancer.

For Antares, a company that just launched in June 2025 as a spin-out from Scorpion Therapeutics, this deal is a monumental validation. Born from the same leadership team and backed by a hefty $177 million Series A financing, Antares is now armed with the resources and the partner to accelerate its mission. The collaboration focuses on developing first-in-class small molecule therapies, a class of drugs that can be administered as pills, against validated but historically intractable oncology targets.

Unlocking the 'Undruggable'

For decades, the blueprint of a cancer cell has revealed numerous proteins that drive tumor growth, but a vast majority of them have remained out of reach for drug developers. These so-called “undruggable” targets lack the conventional pockets or grooves where a typical drug molecule can bind and exert its effect. They represent the high-hanging fruit of oncology, promising immense therapeutic potential if they can be successfully inhibited.

This is precisely the challenge Antares was built to solve. The Boston-based company has developed a sophisticated, multi-pronged discovery platform that integrates several cutting-edge technologies. At its core is expertise in covalent drug discovery, a chemical strategy that designs molecules to form a strong, permanent bond with their target protein. This approach can create highly potent and selective medicines capable of hitting targets that have resisted traditional methods.

Antares’ platform doesn't stop there. It combines this chemical expertise with proprietary screening libraries, advanced chemical proteomics to map drug interactions in living systems, and structure-driven computational chemistry. Layered on top is a purpose-built machine learning suite that analyzes vast datasets to predict which molecules will be most effective, dramatically accelerating the design-build-test cycle of drug discovery. It’s this synthesis of technologies that caught Novartis’s eye.

“Novartis is committed to advancing innovative approaches to cancer drug discovery and expanding the boundaries of what's possible in oncology treatment,” said Fiona Marshall, President of Biomedical Research at Novartis, in the announcement. “We believe this collaboration has the potential to unlock a new wave of targeted therapies and bring meaningful advances to patients.”

A Strategic Alliance Forged in Precision

Beyond the science, the structure of this deal reveals a great deal about the current dynamics in the biopharmaceutical industry. For Antares, the $105 million upfront payment provides a significant infusion of non-dilutive capital, allowing it to aggressively pursue its research without giving up equity. More importantly, the agreement allows the company to continue advancing its own wholly-owned pipeline, ensuring its long-term independence and growth trajectory.

“This collaboration lets us scale that engine alongside Novartis’ world-class development capabilities and global reach, so we can translate our science into transformative therapies for patients faster than either of us could alone,” stated Adam Friedman, M.D., Ph.D., Chief Executive Officer of Antares. His statement underscores the symbiotic nature of the partnership: Antares provides the innovative engine, while Novartis provides the global development and commercialization chassis.

For Novartis, the collaboration is a strategic masterstroke. Large pharmaceutical companies are under constant pressure to replenish their drug pipelines as older products lose patent protection. Rather than relying solely on in-house research, partnering with agile biotechs like Antares provides access to high-risk, high-reward innovation. It allows the pharma giant to tap into a specialized platform for a fraction of the cost it would take to build from scratch, de-risking its entry into one of the most challenging but promising frontiers of oncology. The modest but positive market reaction to Novartis’s stock following the announcement suggests investors see the long-term strategic value in this calculated bet on next-generation science.

A New Horizon for Patient Care

While the scientific and financial implications are profound, the ultimate promise of this collaboration lies in its potential impact on patients. The cancers driven by “undruggable” targets are often the most aggressive and difficult to treat, including certain forms of lung, colorectal, and pancreatic cancer where patients have limited options. A breakthrough in this area would not be an incremental improvement; it would be a paradigm shift, offering hope where little currently exists.

According to the agreement, Antares will lead the initial research to identify and validate drug candidates before Novartis has the option to take them into later-stage development and commercialization. Antares has already signaled its rapid progress, with its own lead program expected to enter the clinic in 2026. While the journey from a preclinical candidate to an approved medicine is long and arduous—often taking a decade or more—this partnership significantly accelerates the process.

By combining Antares’ discovery prowess with Novartis’s extensive clinical trial infrastructure and regulatory expertise, the collaboration aims to shorten the timeline from laboratory breakthrough to patient bedside. For the countless individuals and families affected by cancers that have so far eluded effective treatment, this alliance represents more than just a business deal; it is a critical step forward in the relentless pursuit of a cure.